文献速递类风湿关节炎其他结缔组织病

利妥昔单抗对类风湿关节炎相关间质性肺病进展的影响:单中心10年经验

Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

本研究为单中心观察性研究,评估利妥昔单抗(RTX)治疗类风湿关节炎(RA)相关间质性肺病(RA-ILD)的效果及预后相关因素。在700例接受RTX治疗的RA患者中,56例(8%)存在RA-ILD,治疗后多数患者ILD稳定或改善,进展者多为治疗前已存在严重ILD。

要点

  • RTX治疗后多数RA-ILD患者病情稳定或改善,进展者多与治疗前严重ILD相关。
  • 基线DLCO<46%预测值、UIP型及既往肺进展史与ILD进展相关。
  • RTX治疗期间新发ILD罕见,提示药物可能不促成ILD恶化。

核心结论

  • 在因关节炎接受RTX治疗的RA-ILD患者中,多数患者长期随访期间ILD稳定或改善。
  • 病情恶化或死亡者治疗前ILD最严重,提示药物未促发进展。
  • RTX可能是RA-ILD可接受的治疗选择,需进一步研究。

研究设计与样本

  • 单中心观察性研究,纳入>10年队列中接受RTX治疗的RA患者。
  • 共700例RA患者接受RTX,其中56例存在RA-ILD(患病率8%)。
  • 44/56例有可用的肺部评估数据。

主要发现

  • RTX治疗后新发ILD 3/700例(发生率0.4%)。
  • FVC中位相对变化:治疗前-2.4%,治疗后+1.2%(P=0.025)。
  • DLCO中位相对变化:治疗前-4.4%,治疗后-1.3%(P=0.045)。
  • 治疗后23/44例(52%)稳定,7/44例(16%)改善,14例(32%)进展。
  • 9/56例(16%)死于进展性ILD。

关键数值与推荐

  • 进展定义为:FVC下降>10%预测值或DLCO下降>15%预测值、ILD评分恶化或死于进展性ILD。
  • 与ILD进展相关的因素:UIP影像模式、既往肺进展史、RTX前DLCO<46%预测值。
  • 进展者中11/14例(79%)治疗前为严重ILD[中位DLCO 42%预测值(IQR 41-49)]。

临床怎么用

  • 对RA-ILD患者,RTX治疗期间多数病情稳定或改善,可考虑作为治疗选择。
  • 治疗前应评估DLCO、影像模式及既往肺进展史以识别进展高风险患者。
  • 严重ILD患者(如DLCO<46%预测值)使用RTX需密切监测病情进展。

局限性

  • 单中心观察性研究,样本量有限(56例RA-ILD)。
  • 仅44/56例有可用肺部评估数据,可能存在信息偏倚。
  • 缺乏对照组,无法确定因果关系。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effect of rituximab (RTX) in patients with RA-related interstitial lung disease (RA-ILD) and identify factors associated with outcome after treatment. METHODS: An observational study of patients with RA-ILD was conducted from a cohort of RTX-treated RA patients in a single centre for >10 years. Progression was defined by any of the following: a decrease of pre-RTX forced vital capacity (FVC) >10% or diffusion capacity of carbon monoxide (DLCO) >15% predicted, worsening of the ILD score or death from progressive ILD. RESULTS: Of 700 RA patients treated with RTX, 56 had RA-ILD (prevalence = 8%). After RTX, new ILD was diagnosed in 3/700 patients (incidence = 0.4%). Data for lung assessment were available for 44/56 patients. The median relative change pre- and post-RTX for FVC were -2.4% and +1.2% ( P = 0.025) and for DLCO were -4.4% and -1.3% ( P = 0.045). Post-RTX, 23/44 (52%) were stable and 7/44 (16%) had improved. Of the 14 (32%) with ILD that progressed, 9/56 (16%) were deaths due to progressive ILD. Factors associated with ILD progression were radiologic pattern of usual interstitial pneumonia, a previous history of lung progression and pre-RTX DLCO <46% predicted. Of those whose ILD progressed, 11/14 (79%) had severe ILD before RTX [median DLCO 42% predicted (interquartile range 41-49)]. CONCLUSION: In this cohort of patients where RTX was given for arthritis, most patients with ILD pre-RTX remained stable/improved after treatment over a prolonged follow-up period. Patients who deteriorated/died had the most severe ILD pre-RTX, suggesting the drug was not contributory. RTX appears to be an acceptable therapeutic choice for patients with RA-ILD and further studies are warranted.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Md Yusof MY, Kabia A, Darby M, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. Rheumatology (Oxford). 2017. PMID: 28444364. doi:10.1093/rheumatology/kex072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。